CYT Cyteir Therapeutics Inc

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2023

 

 

Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-40499	45-5429901
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
99 Hayden Ave, Building B, Suite 450
Lexington, Massachusetts				02421
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 285-4140

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		CYT		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

---

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 14, 2023, Cyteir Therapeutics, Inc. (the "Company") held its previously announced Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present.

At the Annual Meeting, the stockholders of the Company voted on the following proposals: (i) to elect Racquel Bracken, Jean George and Timothy Romberger as Class II directors of the Company's board of directors, each for a three year term ("Proposal 1"); and (ii) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 ("Proposal 2").

For Proposal 1, the Company's stockholders elected the nominees listed below to the Company's board of directors. The votes cast at the Annual Meeting for Proposal 1 were as follows:

 

Nominees		For		Against		Abstain		Broker Non-Votes
Racquel Bracken		23,987,021		1,029,385		14,599		2,102,879
Jean George		23,263,587		1,752,793		14,625		2,102,879
Timothy Romberger		23,037,284		1,983,622		10,099		2,102,879

 

 

For Proposal 2, the Company's stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The votes cast at the Annual Meeting for Proposal 2 were as follows:

 

For		Against		Abstain		Broker Non-Votes
25,631,370		1,487,568		14,946		—

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CYTEIR THERAPEUTICS, INC.
Date:	June 14, 2023	By:	/s/ Adam M. Veness, Esq.
			Name: Adam M. Veness, Esq. Title: General Counsel and Secretary

 

---